500 patients66,097 observations150 daysLIVE

Patient P-03376

Synthetic patientONX-7 · Day 146 · 25–34 · M · baseline S10Steering view · 3DOpen companion preview
Is the drug working?

Immune response 26 at the day-84 endpoint (observed).

Why not responding?

Not responding because: poor metabolizer (exposure outside the modelled range); IL6 high-expression variant (inflammatory tone); no butyrate producers (2 keystone absent, butyrate 648 CPM); Escherichia coli above range (LPS load). The drug never had the barrier to work with.

Is a side effect starting?

Drift detected on day 41 (trajectory left the model); nothing reported yet — the window to act is open.

Still taking it?

3 of 4 scheduled doses in the last 60 days are biologically confirmed (75%). Dose signature: resting HR +5 bpm, HRV −8 ms.

last 4 doses · green confirmed · amber logged only · red missed
Plan for this patient
stable, no actionrecommendowner · Companionreview day 153Human Model →
Next action
No action indicated; maintain.
Kept if

Trajectory is stable relative to similar patients; keep the current content.

Daily to-dos in the companion
  • 🍽Keep meals regular; three to four moderate portions spaced through the day
  • 🍽Include a cooked vegetable portion with each main meal
  • Log the daily check-in; one line is enough
  • A 15-minute walk after lunch
  • 💊Take the scheduled dose as agreed with your care team
  • 💊No additional supplements this week
Adherence
87% stable

Adherence is not the problem.

Changes the plan if

sleep quality falling under 35 while GI rises

LLIFE OS insight
grounded · add an LLM key for prose

P-03376 is on day 146 of ONX-7 (NR, baseline S10): response unstable, tolerance deteriorating, GI deteriorating. Over 14 days response moved +9 and GI +6; discontinuation risk is 25%. The state is between basins, heading towards restoration, after diverging from the model on day 41.

Biology sets the gain: IL6 high-expression variant, Poor metabolizer, Low butyrate capacity; butyrate capacity 26/100, diversity 3.0. Pushing it down: Escherichia coli 14.421% (LPS load) (-38.2), Low butyrate capacity (-34.1), Poor metabolizer (-24.8). Pulling it up: Protein (supports) (+22.6). From the daily log: protein -4.8 GI next day, fat +4.2 GI next day, caffeine +3.8 GI next day.

No action has been tried yet.

No action is indicated now; the trajectory is stable relative to similar patients.

Therapy response
Unstable
Tolerance
Deteriorating
GI state
Deteriorating
Inflammatory state
Favorable
Nutritional resilience
Declining
Discontinuation risk
25%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted · dose (infusion on day 1 of each 14-day cycle)
  1. Day 0 ONX-7 startedBaseline state S10
  2. Day 41 Trajectory diverged from predictionObserved response fell below the model's expected path.

What changed?

Trajectory began diverging from predicted response on Day 41.

Primary contributors, last 14 days
  • Nutritional resilience-7
  • GI instability+6
  • Toxicity+6
  • Inflammatory activity-2
  • Treatment adherence+2

What helped?

No interventions yet.

    LIFE OS recommendation
    No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.

    Daily trackers

    Asset settings

    The trackers this program marks as important, last 14 days vs the 14 before.

    Energy level
    Daily log
    4.6/10
    worsening · -0.8 vs previous 14 d
    Stress level
    Daily log
    5/10
    worsening · +0.6 vs previous 14 d
    Pessimism score
    Daily log
    5.1/10
    stable · +0.1 vs previous 14 d
    Sleep quality
    Wearable
    26.2/100
    worsening · -7.7 vs previous 14 d
    Libido
    Daily log
    3.9/10
    worsening · -0.7 vs previous 14 d
    HRV
    Wearable
    40.4 ms
    worsening · -3.1 vs previous 14 d
    Toxicity
    Blood
    14.4/100
    worsening · +3.0 vs previous 14 d
    This trajectory is decaying — what would help, what would not
    Steering view →

    Heading towards restoration · 64 from the failing basin, 42 from restoration.

    Would help
    • No untried action with strong evidence. Compose one from primitives.
    • More protein
      GI -4.8 next day on high-intake days · n 22
    Would not help
    • AD-05 Adherence Support
      only 38% improved among 8 similar
    • Keep fat low
      GI +4.2 next day on high-intake days · n 20
    • Keep caffeine low
      GI +3.8 next day on high-intake days · n 19
    State influencers · digestive

    Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

    • Protein
      -4.8supporter · 95%
    • Dietary fat load
      +4.2detractor · 95%
    • Caffeine
      +3.8detractor · 95%
    • Lactose
      +1.7no signal · 44%
    • Histamine load
      -1.3no signal · 39%
    • Alcohol
      -0.7no signal · 19%

    DeepGene damage signature

    The metagenomic + host-DNA read-out that initializes this patient's biology and, on retest, measures whether the steering worked.

    Damage score · retest day 90
    37/100
    vs baseline (day 0)
    -20
    8 improved · 0 worsened
    synthetic signature · consistent with this patient's biology
    • 2 opportunists above range: Escherichia coli, Klebsiella pneumoniae
    • 2 keystone species absent
    • Shannon 2.77 (expected ≥ 3)
    • 6 resistance genes
    Pathogens / opportunists2/5
    from 5
    Keystone species2/8
    from 3
    Diversity1/2
    Metabolic modules0/4
    Vitamin synthesis2/7
    from 3
    Oral translocation1/1
    Host DNA0/1
    Tissue recycling0/1
    from 1
    Central mechanisms0/2
    Virulence factors2/2
    from 3
    Antibiotic resistance genes6/6
    from 7
    Genetic predisposition2/2
    Opportunists above range
    Escherichia coli 14.421% AR
    Klebsiella pneumoniae 4.326% AR
    Keystone species absent
    Akkermansia muciniphila, Bifidobacterium longum
    Capacity
    Shannon 2.77 · butyrate 648 CPM · SCFA 1072
    2 vitamins below
    Host & mechanisms
    tissue recycling 32/100
    oral translocation 3.29% AR
    6 resistance genes · 2 virulence factors

    Biological layers

    Which pathways look influenced, and by which layer of this person's biology.

    Pathways under pressure
    • Butyrate / short-chain fatty acid production 60
      • MicrobiomeButyrate capacity 26/100
      • MicrobiomeF. prausnitzii depleted
    • Drug metabolism and exposure 40
      • DNACYP2D6 poor metabolizer → higher exposure
    • Autonomic recovery 40
      • Wearable2,896 steps/day
      • WearableShort sleep window
    • Inflammatory signalling 25
      • DNAIL6 -174 variant raises baseline inflammatory tone
    • Mucosal barrier integrity 10
      • WearableSleep 5.6 h, below personal baseline
    DNA
    Fictional pharmacogenomic panel
    • IL6 -174 G/C
      Higher inflammatory tone
    • CYP2D6 Poor metabolizer
      Higher exposure at standard dose
    • MTHFR C677T
      Reduced folate turnover
    Microbiome
    Shannon diversity 3 · butyrate capacity 26/100
    • Akkermansia muciniphilaNormal
    • Faecalibacterium prausnitziiLow
    • Bacteroides fragilisNormal
    • Bifidobacterium longumNormal
    • EnterobacteriaceaeNormal
    Wearable, last 14 days
    daily evolution fed into the runtime
    HRV
    38 ms
    Sleep
    5.6 h
    Steps
    2,923
    Resting HR
    64 bpm
    Daily log: GI score 26, nutritional resilience 61, adherence 87.

    What this patient sees in NostraAI

    The content that steers the trajectory: what to eat, what to do, what to take.

    Open companion preview
    What to eat
    • Keep meals regular; three to four moderate portions spaced through the day
    • Include a cooked vegetable portion with each main meal
    • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
    • Avoid known triggers for now: fried or oily food, dairy, alcohol
    What to do
    • Log the daily check-in; one line is enough
    • A 15-minute walk after lunch
    • Protect a 7.5-hour sleep window; screens off 30 minutes before
    • Keep hydration steady: small amounts through the day rather than large volumes at once
    What to take
    • Take the scheduled dose as agreed with your care team
    • No additional supplements this week
    • Fictional demo item: continue vitamin D as before

    284 biologically similar trajectories

    Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

    PatientSimilarityBaselineInterventionOutcomeResponse today
    P-0342053%S0133
    P-0337852%S0132
    P-0324350%S0136
    P-0329344%S0130
    P-0317043%S01ME-01improved31
    P-0314040%S0128
    P-0327035%S01AD-05no change37
    P-0316134%S0131
    P-0310829%S01BR-03no change60
    P-0312027%S0166
    P-0325127%S0159
    P-0331927%S0158